Loading clinical trials...
Loading clinical trials...
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be t...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Ra Pharmaceuticals
NCT05876312 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06312644 · Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, and more
NCT03520647 · Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), and more
NCT07152288 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06294301 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
Investigative Site
Duarte, California
Investigative Site
Los Angeles, California
Investigative Site
Chicago, Illinois
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions